Suramin
QP51AE02 (WHO ) | |
Identifiers | |
---|---|
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Suramin is a
Suramin causes a fair number of side effects.
Suramin was made at least as early as 1916.
Medical uses
Suramin is used for treatment of human
It has been used in the treatment of
Pregnancy and breastfeeding
It is unknown whether it is safe for the baby when a woman takes it while breastfeeding.[2]
Adverse reactions
The most frequent adverse reactions are nausea, vomiting, diarrhea, abdominal pain, and a feeling of general discomfort. It is also common to experience various sensations in the skin, from crawling or tingling sensations, tenderness of palms and the soles, and numbness of hands, arm, legs or feet.[10] Other skin reactions include skin rash, swelling and stinging sensation.[10] Suramin can also cause loss of appetite and irritability.[10] Suramin causes non-harmful changes in urine during use, specifically making the urine cloudy.[10] It may exacerbate kidney disease.[11]
Less common side effects include extreme fatigue, ulcers in the mouth, and painful tender glands in the neck, armpits and groin.[10] Suramin uncommonly affects the eyes causing watery eyes, swelling around the eyes, photophobia, and changes or loss of vision.[10]
Rare side effects include hypersensitivity reactions causing difficulty breathing. Other rare systemic effects include decreased blood pressure, fever, rapid heart rate, and convulsions.[10] Other rare side effects include symptoms of liver dysfunction such as tenderness in upper abdomen, jaundice in eyes and skin, unusual bleeding or bruising.[10]
Suramin has been applied clinically to HIV/AIDS patients resulting in a significant number of fatal occurrences and as a result the application of this molecule was abandoned for this condition.[12]
Pharmacokinetics
Suramin is not orally bioavailable and must be given intravenously. Intramuscular and subcutaneous administration could result in local tissue inflammation or necrosis [citation needed]. Suramin is approximately 99-98% protein bound in the serum and has a half-life of 41–78 days average of 50 days; however, the pharmacokinetics of suramin can vary substantially between individual patients. Suramin does not distribute well into cerebral spinal fluid and its concentration in the tissues is equivalently lower than its concentration in the plasma. Suramin is not extensively metabolized and about 80% is eliminated via the kidneys.[11]
Chemistry
The molecular formula of suramin is C51H40N6O23S6. It is a
The
Mechanism of action
The mechanism of action for suramin is unclear, but it is thought that parasites are able to selectively uptake suramin via receptor-mediated endocytosis of drug that is bound to low-density lipoproteins and, to a lesser extent, other serum proteins.[11] Once inside parasites, suramin combines with proteins, especially trypanosomal glycolytic enzymes, to inhibit energy metabolism.[16]
History
Suramin was first made by the chemists Oskar Dressel, Richard Kothe and Bernhard Heymann at
Research
It is also used as a research
Suramin was studied as a possible treatment for prostate cancer in a clinical trial.[23]
Suramin has been studied in a mouse model of
Suramin is a reversible and competitive protein-tyrosine phosphatase (PTPases) inhibitor, also is the potent inhibitor of sirtuins, purified topoisomerase II and SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).[29]
References
This article has an unclear citation style. (May 2017) |
- ^ a b "Suramin Injection Advanced Patient Information". Drugs.com. 3 January 2020. Retrieved 11 January 2020.
- ^ a b c d e f "Micromedex Detailed Drug Information for the Consumer: Suramin (Injection route)". PubMed Health. 1 November 2016. Archived from the original on 8 September 2017.
- ^ a b "Our Formulary Infectious Diseases Laboratories CDC". www.cdc.gov. 22 September 2016. Archived from the original on 16 December 2016. Retrieved 30 November 2016.
- ^ ISBN 9780471490791. Archivedfrom the original on 30 November 2016.
- ISBN 9783540489948. Archivedfrom the original on 30 November 2016.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Trypanosomiasis, human African (sleeping sickness)". World Health Organization. February 2016. Archived from the original on 4 December 2016. Retrieved 7 December 2016.
- ^ "CDC Infectious Diseases Laboratory: Our Formulary". CDC. Archived from the original on 8 November 2016. Retrieved 8 November 2016.
- ^ PMID 21628620.
- ^ a b c d e f g h "Suramin Injection Advanced Patient Information - Drugs.com". Archived from the original on 8 November 2016. Retrieved 8 November 2016.
- ^ ISBN 9780071769396.
- PMID 3548350.
- PMID 15072843.
- PMID 16250663.
- .
- ISBN 9780071802161.
- ISBN 9780471899792.
- ^ Fourneau E, Théfouël VJ, Vallée J (1924). "Sur une nouvelle série de médicaments trypanocides". Comptes Rendus des Séances de l'Académie des Sciences. 178: 675.
- from the original on 8 September 2017.
- PMID 16968944.
- from the original on 18 November 2016.
- PMID 16056233.
- S2CID 29107328.
- ^ LaFee S, Buschman H (26 May 2017). "Researchers Studying Century-Old Drug in Potential New Approach to Autism". UC San Diego Health. Archived from the original on 1 June 2017.
- PMID 24937094.
- PMID 28695149.
- ^ "Q and A - Suramin and Autism". UC Health - UC San Diego. Retrieved 27 July 2021.
- PMID 37932739.
- ^ "Suramin sodium salt". Selleck Chemicals.
Further reading
- Zhang YL, Keng YF, Zhao Y, Wu L, Zhang ZY (May 1998). "Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases". The Journal of Biological Chemistry. 273 (20): 12281–12287. PMID 9575179.
External links
- Suramin sodium National Cancer Institute